Using Predictive Modeling to Examine IV Ketamine and Esketamine for the Prevention of Postpartum Depression
Intravenous ketamine or esketamine given at the time of cesarean delivery reduced risk for postpartum depression; predictive models are needed to determine which women are most likely to benefit from this intervention.
FDA Approves Zuranolone for the Treatment of Postpartum Depression
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
Weekly Roundup for August 4, 2023: Recent Publications in Women’s Mental Health
Every week we review the most recent publications in women’s mental health.
Is Remeron (Mirtazapine) Safe to Use During Pregnancy? New Data
This study provides reassuring data on the use of mirtazapine during pregnancy, demonstrating no association between exposure and risk of major malformations or pregnancy loss.
More Data on Zuranolone for Postpartum Depression: When Will It Hit the Market?
In women with severe postpartum depression, zuranolone was associated with improvements in depression beginning at day 3. FDA to make a decision next week.
Weekly Roundup for July 28, 2023: Recent Publications in Women’s Mental Health
Every week we review the most recent publications in women’s mental health.